HCRN GU20-436
NePtune: A Phase 2 Study of Neoadjuvant PARP Inhibition followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with BRCA1/2 Gene Alterations
Status: Open to Accrual
Learn More:
- Clinicaltrials.gov: #NCT05498272
Study Contact: studies@hoosiercancer.org; (317) 921-2050.
Facebook
Hoosier Cancer Research Network on Facebook
Linked In
You Tube
Twitter